Protagonist Therapeutics (NASDAQ:PTGX) Downgraded to Hold at ValuEngine

ValuEngine cut shares of Protagonist Therapeutics (NASDAQ:PTGX) from a buy rating to a hold rating in a research note published on Thursday, ValuEngine reports.

PTGX has been the topic of a number of other research reports. HC Wainwright assumed coverage on shares of Protagonist Therapeutics in a research note on Monday, July 8th. They set a buy rating and a $23.00 price target on the stock. BidaskClub downgraded shares of Protagonist Therapeutics from a hold rating to a sell rating in a research note on Thursday. Stifel Nicolaus upgraded shares of Protagonist Therapeutics from a hold rating to a buy rating and lifted their price target for the stock from $11.00 to $17.00 in a research note on Wednesday, May 8th. Finally, Zacks Investment Research downgraded shares of Protagonist Therapeutics from a buy rating to a hold rating in a research note on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $17.17.

Shares of Protagonist Therapeutics stock traded down $0.21 during midday trading on Thursday, hitting $10.35. The company had a trading volume of 96,678 shares, compared to its average volume of 196,042. The company’s 50 day moving average price is $12.29. The company has a market cap of $259.70 million, a PE ratio of -5.95 and a beta of 1.88. The company has a current ratio of 5.02, a quick ratio of 5.02 and a debt-to-equity ratio of 0.07. Protagonist Therapeutics has a 1-year low of $5.49 and a 1-year high of $14.36.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.01. The business had revenue of $1.56 million for the quarter, compared to the consensus estimate of $2.50 million. Protagonist Therapeutics had a negative net margin of 209.02% and a negative return on equity of 40.78%. Equities analysts predict that Protagonist Therapeutics will post -2.07 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Northern Trust Corp boosted its stake in Protagonist Therapeutics by 17.2% during the fourth quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock worth $234,000 after buying an additional 5,084 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its stake in shares of Protagonist Therapeutics by 75.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock valued at $132,000 after purchasing an additional 8,450 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Protagonist Therapeutics by 1,675.5% in the 1st quarter. Bank of Montreal Can now owns 11,026 shares of the company’s stock valued at $139,000 after purchasing an additional 10,405 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Protagonist Therapeutics by 94.3% in the 4th quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock valued at $178,000 after purchasing an additional 12,819 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in shares of Protagonist Therapeutics by 8.8% in the 4th quarter. BlackRock Inc. now owns 260,548 shares of the company’s stock valued at $1,754,000 after purchasing an additional 21,126 shares in the last quarter. Hedge funds and other institutional investors own 64.39% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Featured Article: What is the Federal Reserve?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.